Panagora Asset Management Inc. Increases Position in IQVIA Holdings Inc. $IQV

Panagora Asset Management Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 192,780 shares of the medical research company’s stock after buying an additional 79,237 shares during the quarter. Panagora Asset Management Inc.’s holdings in IQVIA were worth $43,455,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the fourth quarter valued at $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter valued at $27,000. Activest Wealth Management lifted its position in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new position in IQVIA during the fourth quarter valued at $35,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on IQV shares. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research report on Thursday, May 7th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. HSBC set a $210.00 target price on shares of IQVIA in a research report on Wednesday, June 3rd. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $224.13.

IQVIA Stock Down 1.9%

IQV opened at $178.07 on Tuesday. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50-day moving average price of $173.65 and a 200 day moving average price of $193.06. The company has a market cap of $29.72 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.